WEDNESDAY, June 16 (HealthDay News) -- Zotarolimus-eluting stents are not inferior to everolimus-eluting stents in terms of clinical outcomes at 12 months or angiographic outcomes at 13 months, according to research published online June 16 in the New England Journal of Medicine.
Patrick W. Serruys, M.D., of the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues conducted a multicenter non-inferiority study of 2,292 patients with minimal exclusion criteria randomized to undergo coronary stenting with either zotarolimus-eluting or everolimus-eluting coronary stents. The primary end point was 12 month target lesion failure, defined clinically as a composite of cardiac death, myocardial infarction, or symptomatic need for a revascularization procedure. The secondary end point was extent of in-stent stenosis at 13 months, defined angiographically.
With reference to the primary end point, the researchers found the zotarolimus-eluting stents to be non-inferior to everolimus-eluting stents, with events in 8.2 percent of patients with zotarolimus-eluting stents and 8.3 percent of patients with everolimus-eluting stents. With reference to the secondary end point, zotarolimus-eluting stents were found to be non-inferior to everolimus-eluting stents in the degree of in-stent stenosis. There were no significant differences between the two types of stents in regards to adverse effects.
"Although our findings are hypothesis-generating and require additional investigation, definitive conclusions will be obtained only from longer-term follow-up in large patient populations in studies that have sufficient statistical power to detect differences in rates of stent thrombosis," the authors write.
The study was supported by Medtronic CardioVascular.
Abstract
Full Text
